Solventum Corp（SOLV）财务数据SOLVSolventum Corp

Solventum Corporation (SOLV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is MedSurg, accounting for 62.1% of total sales, equivalent to $1.37B. Other significant revenue streams include Dental Solutions and Health Information Systems. Understanding this composition is critical for investors evaluating how SOLV navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Solventum Corporation maintains a gross margin of 58.62%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.49%, while the net margin is 4.21%. These profitability ratios, combined with a Return on Equity (ROE) of 33.96%, provide a clear picture of how effectively SOLV converts its operational activities into shareholder value.

In the context of the broader market, SOLV competes directly with industry leaders such as EHC and BTSG. With a market capitalization of $14.61B, it holds a leading position in the sector. When comparing efficiency, SOLV's gross margin of 58.62% stands against EHC's 90.20% and BTSG's 12.72%. Such benchmarking helps identify whether Solventum Corporation is trading at a premium or discount relative to its financial performance.

The company reported Q2 2026 earnings with a revenue of $2.2 billion, reflecting a 9.5% year-over-year organic growth, and an EPS of 2.55, which exceeded expectations by 33.51%. Gross margin improved to 58.62% in Q2 2026, indicating strong profitability.